Pain and osteoarthritis: New drugs and mechanisms

Current Opinion in Rheumatology

Volumn 16, Issue 5, 2004, Pages 628-633

  Hinz, Burkhard ^a   Brune, Kay ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

5 lipoxygenase; Cyclooxygenase 2; Osteoarthritis; Pain

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ARTHRALGIA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME SYNTHESIS; FATTY ACID SYNTHESIS; HUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; LIPOXYGENASE INHIBITORS; OSTEOARTHRITIS; PAIN;

EID: 4344645732     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000136130.95746.14     Document Type: Review

References (52)

1. Hinz B, Brune K: Cyclooxygenase-2: ten years later. J Pharmacol Exp Ther 2002, 300:367-375.
2. 2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 2002, 136:287-295.
3. 2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002, 46:1789-1803.
4. Jovanovic DV, Mineau F, Notoya K, et al.: Nitric oxide induced cell death in human osteoarthritic synoviocytes is mediated by tyrosine kinase activation and hydrogen peroxide and/or superoxide formation. J Rheumatol 2002, 29:2165-2175.
5. Hinz B, Brune K: Non-steroidal anti-inflammatory drugs: old and new. In: Isenberg DH, Maddison PJ, Woo P, eds. Oxford Textbook of Rheumatology. 3rd ed. Oxford: Oxford University Press; 2004:442-450.
6. Beiche F, Scheuerer S, Brune K, et al.: Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996, 390:165-169.
7. 2. J Neurosci 2001, 21:1750-1756.
8. 2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 2002, 5:34-40.
9. He W, Pelletier JP, Martel-Pelletier J, et al.: Synthesis of interleukin 1β, tumor necrosis factor-α, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol 2002, 29:546-553.
10. 4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum 2002, 46:1804-1812.
11. Cochrane DJ, Jarvis B, Keating GM: Etoricoxib. Drugs 2002, 62:2637-2651.
12. Ding C, Jones G: Lumiracoxib (Novartis). Drugs 2002, 5:1168-1172.
13. Ormrod D, Wellington K, Wagstaff AJ: Valdecoxib. Drugs 2002, 62:2059-2071.
14. Ahuja N, Singh A, Sing B: Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 2003, 55:859-894.
15. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther 2003, 25:817-851.
16. Sikes DH, Agrawal NM, Zhao WW, et al.: Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002, 14:1101-1111.
17. Pavelka K, Recker DP, Verburg KM: Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 2003, 42:1207-1215.
18. Hunt RH, Harper S, Callegari P, et al.: Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003, 17:201-210.
19. Hunt RH, Harper S, Watson DJ, et al.: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003, 98:1725-1733.
20. Rordorf C, Kellett N, Mair S, et al.: Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003, 18:533-541.
21. Atherton C, Jones J, McKaig B, et al.: Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2004, 2:113-120.
22. Werner U, Werner D, Pahl A, et al.: Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002, 16:56-60.
23. Werner U, Werner D, Rau T, et al.: Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003, 74:130-137. A recent proband study reporting an inhibitory effect of celecoxib on the metabolism of the CYP2D6 substrate metoprolol.
24. Chang DJ, Fricke JR, Bird SR, et al.: Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 2001, 23:1446-1455.
25. Daniels SE, Desjardins PJ, Talwalker S, et al.: The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002, 133:611-621.
26. Makarowski W, Zhao WW, Bevirt T, Recter DP: Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002, 10:290-296.
27. Leung AT, Malmstrom K, Gallacher AE, et al.: Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002, 18:49-58.
28. Zacher J, Feldman D, Gerli R, et al.: A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003, 19:725-736.
29. Tannenbaum H, Berenbaum F, Reginster JY, et al.: Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis 2004. Epub ahead of print.
30. Dooley M, Spencer CM, Dunn CJ: Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001, 61:1351-1378.
31. Hinz B, Rau T, Auge D, et al.: Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003, 74:222-235. A recent study showing preferential COX-2 inhibition by aceclofenac as a result of limited but sustained biotransformation to diclofenac. Possible implications of the results with respect to the improved gastrointestinal tolerability of aceclofenac are discussed.
32. Schattenkirchner M, Milachowski KA: A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol 2003, 22:127-135.
33. Dingle JT: The effect of NSAID on human articular cartilage glycosaminoglycan synthesis. Eur J Rheumatol Inflamm 1996, 16:47-52.
34. Sanchez C, Mateus MM, Defresne MP, et al.: Metabolism of human articular chondrocytes cultured in alginate beads: longterm effects of interleukin 1β and nonsteroidal antiinflammatory drugs. J Rheumatol 2002, 29:772-782.
35. Akimoto H, Yamazaki R, Hashimoto S, et al.: 4′-Hydroxy aceclofenac suppresses the interleukin-1 -induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol 2000, 401:429-436.
36. Yamazaki R, Kawai S, Mizushima Y, et al.: A major metabolite of aceclofenac, 4′-hydroxy aceclofenac, suppresses the production of interstitial procollagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res 2000, 49:133-138.
37. Gonzalez E, de la Cruz C, de Nicolas R, et al.: Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994, 41:171-178.
38. Gomez-Gaviro MV, Gonzalez-Alvaro I, Dominguez-Jimenez C, et al.: Structure-function relationship and role of tumor necrosis factor-alpha- converting enzyme in the down-regulation of L-selectin by non-steroidal antiinflammatory drugs. J Biol Chem 2002, 277:38212-38221.
39. Huskisson EC, Irani M, Murray F: A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflamm 2000, 17:1-7.
40. Lemmel EM, Leeb B, De Bast J, Aslanidis S: Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin 2002, 18:146-153.
41. Schnitzer TJ: Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002, 23(suppl 4):S24-S30.
42. Brandt K: Paracetamol in the treatment of osteoarthritis pain. Drugs 2003, 63(special no 2):23-41.
43. Zhang W, Jones A, Doherty M: Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004. Epub ahead of print March 5.
44. 2 release after peripheral noxious stimulation. Anesthesiology 1999, 91:231-239.
45. Chandrasekharan NV, Dai H, Roos KL, et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002, 99:13926-13931.
46. Dinchuk JE, Liu RQ, Trzaskos JM: COX-3: in the wrong frame in mind. Immunol Lett 2003, 86:121.
47. Schwab JM, Beiter T, Linder JU, et al.: COX-3: a virtual pain target in humans? FASEB J 2003, 17:2174-2175. An interesting paper that questions the existence of a catalytically active form of COX-3 in humans.
48. 2 synthases. Proc Natl Acad Sci U S A 2002, 99:7130-7135.
49. Tries S, Neupert W, Laufer S: The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002, 51:135-143.
50. Lajeunesse D, Martel-Pelletier J, Fernandes JC, et al.: Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis. Ann Rheum Dis 2004, 63:78-83.
51. Boileau C, Martel-Pelletier J, Jouzeau JY, et al.: Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of proapoptotic factors. J Rheumatol 2002, 29:1446-1453.
52. Pelletier JP, Boileau C, Brunet J, et al.: The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004, 34:527-538. A study showing concomitant inhibition of bone resorption and suppression of MMP-13 levels by the LOX/COX inhibitor licofelone.